Linked
`
`People ~
`
`Ken
`
`Phares
`
`Ken Phares
`Vice President Pharmaceutical Developmentat United
`Therapeutics Corporation
`Hillsborough, North Carolina
`
`500+ connections
`
`United Therapeutics
`Corporation
`
`fa University of North Carolina at
`ChapelHill
`
`Gi Whensigningin, you can chooseto viewtheprofile in private mode.
`
`Activity
`
` ONEOF OURS{So much Courage,bravery & honorin one Picture =23@-*
`
`https://Inkd.in/gMK9aEQ Qe
`Liked by Ken Phares
`
`I wouldlike to take a momentof reflection to thank my customers and
`vendors. Thereis a saying somewhere about you are measured by how
`you perform...
`Liked by Ken Phares
`
`People also viewed
`Betsy Eades
`Director, Head of Business
`Developmentat United
`Therapeutics Corporation
`Raleigh-Durham-ChapelHill Area
`Noah Byrd
`Associate Vice President, Global
`Regulatory Affairs at United
`Therapeutics Corporation
`Durham, NC
`MarkBattaglia
`Sr Director, Global Data Operations
`at United Therapeutics
`Raleigh, NC
`Dean Bunce
`EVPGlobal Regulatory Affairs ,
`United Therapeutics.
`Apex, NC
`Kevin Gray
`Vice President, Trade Relations and
`Patient Program Managementat
`United Therapeutics.
`Raleigh, NC
`Maria Bailey
`Germanand Electives Teacherat
`K12International Academy
`Durham, NC
`Brian Greer, PMP
`Project Engineer at C&l Engineering
`in Louisville, Kentucky
`Louisville Metropolitan Area
`Mitchell Ronaldson
`Field Supervisor/ Construction
`Experience
`Management
`British Columbia, Canada
`Vice President Pharmaceutical Development
`a,
`United Therapeutics Corporation
`Jeff. "Lars" Larson
`NMAS,
`Jun 2001- Present:19 years 11 months
`Clearwater, MN
`55 TW. Alexander Drive, RTP, NC 27709
`Responsibilities included: preformulation, formulation development, analytical and
`Jessica Meyer
`Head of Procurementat United
`bioanalytical method development and writing and editing CMC sectionsof regulatory
`Therapeutics (Purchasing,
`submissions such as INDs, CTDs, supplements, amendments, and annual reports.
`Outsourcing & Contracts Divisions)
`Managed:clinical supplies, process scale up, and packaging.
`Raleigh-Durham-ChapelHill Area
`Specific activities include:
`+ Coordinated pharmaceutical developmentactivities from API characterization to drug
`Show moreprofiles ~
`product developmentand processscale up.
`+ Analytical activities included characterization of API and drug productalong with in- vitro.
`testing of the drug product.
`+ Bioanalytical activities included managing the analysis of samplesfrom toxicology and
`clinical supplies.
`+ Managetimelines and workflow for theseactivities across various projects.
`Show less +
`
`9664660©@
`
`Others named Ken Phares
`
`e Ken Phares
`Managerof Patient Nutrition
`Services at WVUMedicine
`United States.
`
`Adjunct Associate Professor; Eshelman School of Pharmacy
`Nutrition Manager at WVUH-Ruby
`e Ken Phares
`
`Memorial Hospital
`University of North Carolina at ChapelHill
`Morgantown, WV
`Jan 2019 - Present.2 years 4 months
`Ken Phares
`ChapelHill, NC
`~-Showreom Auto Detailing
`Lectures in advanced pharmaceutics classes
`United States
`SeniorScientist
`Triangle Pharmaceuticals
`May 1999 - Jun 2001. 2 years 2 months
`Durham, NC
`Preformulation and formulation of antiviral compounds. The preformulation work involved
`assessing solubility, stability, polymorphism, and excipient compatibility. The formulations
`developed weresolid- and liquid-dosage forms.
`SeniorScientist
`3M Pharmaceuticals
`Add newskills with these
`May 1996 - May 1999-3 years 1 month
`courses
`Preformulation of compoundsfrom the chemistry department at 3M pharmaceuticals and
`formulation of compoundsselected for development. Preformulation work involved assessing
`solubility in various organic and aqueoussolvents,stability in the solid state and solution, and
`polymorphsereening. Formulation workinvolved incorporation of new chemicalentities into
`solid and semi-solid dosage forms to supporttoxicology andclinical studies. Supervised one
`technician, three B.S. level and one Ph.D.scientist. Contributed to writing the CMC section of
`one NDAand one IND submission to the FDA.
`Show less ~
`
`e Ken Phares
`United States
`
`6 others named KenPhares are on
`LinkedIn
`
`See others named Ken Phares
`
`Microsoft Cognitive
`Services for Developers:
`2 Speech
`
`HTTPEssential Training
`
`
`O— Java EE: BeanValidation
`
`Ken's public profile badge
`Includethis LinkedIn profile on other
`websites
`
`Ken Phares
`2 Vice President Pharmaceutical
`Developmentat United
`Therapeutics Corporation
`Vice President Pharmaceutical
`= Developmentat United Therapeutics
`Corporation
`
`Education
`
`
`
`University of North Carolina at ChapelHill
`Post-doc - Pharmaceutical Chemistry
`1993 - 1995
`Activities and Societies: Under the guidance of Dr. Cho and working undera grant funded by
`PhRMAstudied folate conjugates to enhance absorption.
`
`
`
`University of North Carolina at Chapel Hill
`PhD - Pharmaceutical Chemistry
`1988 - 1993
`
`WestVirginia University
`B.S. . Pharmacy
`1980 - 1985
`
`IPR2020-007
`=
`ChapelHill
`fal University of North Carolina at
`United Therapeutics EX20
`Linked
`Page 10
`Cinnaminson High School
`
`

`

`>
`
`Diploma
`1976 - 1980
`
`Licenses & Certifications
`
`Registered Pharmacist
`-
`
`:
`
`Groups
`Rx&D - Biopharmaceutical, Pharmaceutical and Biotechnology Research and
`1 Development
`
`WVUAlumniTriangle Group.
`
`> amps
`
`American Association of Pharmaceutical Scientists
`
`-
`aa
`
`Pharmaceutical Discussion Group
`
`ot Formulation Research and Development
`
`=)
`
`Pharma Excipients
`Protein Stability
`
`Show fewer groups ~
`
`View Ken'sfull profile
`@ See who you know in common
`' Getintroduced
`48 Contact Kendirectly
`
`Linked[f] ©20: About Accessibility
`
`User Agreement
`
`Priv: ‘antrals
`
`Community Guidelines Language
`
`